HR 9661: To amend the Public Health Service Act to codify that the default expectation for licensure of biological products as biosimilar does not include clinical studies assessing pharmacodynamics or comparative clinical efficacy, and for other purposes.

HR 9661 in plain English: This bill is early in the legislative process and detailed text is not yet available. Sponsor: Rep. Langworthy, Nicholas A. [R-NY-23] (R) · Status: Referred to the House Committee on Energy and Commerce.

Current status in Congress: In committee.